In the News

Cognizin® Citicoline Named "Functional Ingredient to Watch In 2026" By Mintel & Black Swan Data, Showcasing Its Explosive Growth In The Brain Health Category

OmegaQuant to Showcase Personalized Omega-3 Solutions at the Integrative Healthcare Symposium 2026

Nestlé Health Science Launches Landmark Study to Uncover the Impact of Lifestyle on Gut Health

NOW® Survey Uncovers The Wellness And Health Priorities Shaping Consumers' Supplement Use In 2026

New Study Links Higher Omega-3 Levels to Lower Risk of Depression & Anxiety

Vitamin K2’s Proven Benefits are Growing, Yet Recognition has Room to Improve

Cognizin® Citicoline Named "Functional Ingredient to Watch In 2026" By Mintel & Black Swan Data, Showcasing Its Explosive Growth In The Brain Health Category

Kyowa Hakko USA today announced that Cognizin® (citicoline), the branded form of citicoline manufactured by Kyowa Hakko Bio Co., has been recognized as a leading "Functional Ingredient to Watch in 2026" by global market intelligence firm Mintel and consumer analytics leader Black Swan Data. This third?party validation highlights Cognizin®'s position at the center of the rapidly growing brain health and mental performance market.
According to the Mintel/Black Swan analysis, 65% of global product launches featuring Cognizin® include a brain or nervous system benefit, signaling strong and accelerating demand for evidence?based cognitive support. Cognizin® now appears across a wide range of formats, from gummies and lollipops to energy drinks and advanced supplements, making it one of the most versatile and exciting ingredients in the field of functional nutrition today.
"Being named an ingredient to watch in 2026 is more than a nice headline; it confirms what formulators and consumers are already telling us," said Katie Emerson, MS, RD, Senior Manager, Scientific Affairs at Kyowa Hakko USA. "Cognizin® isn't just another nootropic on a crowded shelf. It is a clinically researched, rigorously manufactured ingredient that brands are building entire product stories around. This recognition validates years of investment in science and quality and marks the beginning of Cognizin®'s mainstream breakout."
Data behind the recognition
The Mintel/Black Swan work highlights several key trends shaping Cognizin®'s trajectory:

• Strong brain?health focus: 65% of global Cognizin® launches carry a brain or nervous system claim, making cognitive support the dominant positioning for the ingredient.
• Growing geographic footprint: Most launches are currently concentrated in North America (49%) and Europe (34%), indicating both strong adoption and substantial opportunities for growth in other regions.
• Diverse product formats: Cognizin® primarily appears in nutrition drinks (36%), energy drinks (32%), and supplements (23%), as well as emerging formats such as functional confections and beauty-from-within products.

Recent launches featuring Cognizin® include science-backed products, such as Qunol, BUM Energy, MOSH, and Magic Mind, which showcase how brands use Cognizin® to deliver benefits in everyday settings.
"Seeing Cognizin® across a wide range of formats underscores its versatility and impact," Emerson added. "It tells us cognitive support is no longer niche but has become a baseline expectation."
Why Cognizin® stands out in a crowded nootropics landscape
Cognizin® is a branded form of citicoline, a nutrient that supports the production of phosphatidylcholine, a key component of brain cell membranes and a critical player in brain cell energy. Unlike many generic nootropics, Cognizin® is backed by a substantial research portfolio.
Key differentiators include:

• Clinical evidence: Studies have demonstrated that citicoline can support attention, memory, and cognitive performance, including MRI-based research that shows changes in brain activity.
• Brain energy support studies indicate citicoline can increase brain ATP (cellular energy) by approximately 13%, directly supporting mental energy and focus.
• Non-stimulant profile: Cognizin® delivers cognitive benefits without relying on caffeine or harsh stimulants, making it an attractive option for consumers.
• Quality and consistency: Produced by Kyowa Hakko using proprietary fermentation technology and strict quality controls, Cognizin® offers consistent purity and traceability for brands and consumers.

"In an era where consumers are increasingly skeptical of vague 'brain boosting' claims, Cognizin®'s science?first story matters," Emerson said. "Brands want ingredients that can stand up to evaluation from highly informed shoppers, and Cognizin does exactly that."
The recognition also comes at a moment when mental performance and burnout are front?page topics. Recent workplace and health research shows that employees and consumers are struggling with focus, attention, and mental fatigue.
"2026 is shaping up to be the year people stop accepting mediocre process and scattered thoughts as the new normal," Emerson said. "They are looking for practical, daily tools that help them show up sharp—at work, in the gym, and at home. Cognizin® gives formulators a scientifically grounded way to build those solutions."
Supporting innovator brands worldwide
The "Functional Ingredient to Watch in 2026" designation is already inspiring new collaborations and product concepts across beverages, supplements, and functional foods. Kyowa Hakko USA is expanding its support for partners through:

• Formulation guidance for beverages, powders, gummies, and novel formats
• Science?based marketing assets translating complex research into clear consumer language
• Co?marketing opportunities spotlighting brands that formulate with Cognizin®
• Education initiatives for healthcare professionals, retailers, and formulators

"Some of the most exciting innovations we're seeing right now are coming from brands that understand that cognitive performance is the new energy," Emerson said. "Those brands are choosing Cognizin® because they want their products to be future?proof and aligned with where the market is going, not where it's been."
About Kyowa Hakko USA
Kyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to improving the health and well-being of people worldwide by creating innovative solutions with science and nature. With cutting-edge research capabilities, Kyowa Hakko Bio is committed to developing unique ingredients supported by scientific evidence. For more information, visit kyowa-usa.com.
About Cognizin®
Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of citicoline, a natural substance made endogenously in the body and especially vital to brain health. Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, and attention. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure, and allergen-free. Cognizin® can be sold as a dietary ingredient for supplements, foods, and beverages in the United States and is approved as a novel food ingredient in the EU for food supplements. For more information on Cognizin®, visit Cognizin.com.

SOURCE Kyowa Hakko U.S.A

OmegaQuant to Showcase Personalized Omega-3 Solutions at the Integrative Healthcare Symposium 2026

OmegaQuant, the leader in fatty acid testing and personalized omega-3 assessment, announced today that it will exhibit at the Integrative Healthcare Symposium, taking place in New York City February 19-21. OmegaQuant will be joined by its sister company, Parasol Nutrition, and omega-3 oil supplier partner GC Rieber/VivoMega™, highlighting a comprehensive, personalized omega-3 ecosystem for health practitioners.
Attendees can visit OmegaQuant at Booth #1205 in the Americas Hall of the Hilton NYC Midtown Convention Hall, where the companies will showcase how omega-3 testing, formulation, and high-quality sourcing work together to support precision nutrition in clinical practice.
At the show, OmegaQuant and Parasol Nutrition will share details about a new Personalized Omega-3 Program, designed to help integrative and functional medicine practices deliver data-driven, patient-specific omega-3 recommendations. The program combines OmegaQuant’s blood biomarker testing with customized omega-3 formulations powered by VivoMega oils, enabling clinicians to move beyond generic dosing toward personalized care.
OmegaQuant will also highlight new research linking omega-3 status—measured by the Omega-3 Index—to key areas of clinical interest, including atrial fibrillation, Alzheimer’s disease, and anxiety, reinforcing the role of objective fatty acid testing in cardiovascular, cognitive, and mental health.
In addition to exhibiting, William S. Harris, PhD—co-inventor of the Omega-3 Index and founder of OmegaQuant and the Fatty Acid Research Institute(FARI)—will present on Thursday, February 19th at 11:00 a.m. in the Nassau Conference Room on The Missing Metric in Longevity Medicine: The Omega-3 Index. His session will review the scientific evidence demonstrating how the Omega-3 Index correlates with reduced risk of cardiovascular events, cognitive decline, systemic inflammation, and overall mortality. The presentation will also address how Omega-3 Index testing can enhance personalized care, guide dietary and supplement recommendations, and serve as a measurable endpoint in patient monitoring and chronic disease management.
“The Integrative Healthcare Symposium is an ideal venue to showcase how testing, formulation, and clinical science come together to support personalized omega-3 care,” said Jason Polreis, CEO, OmegaQuant. “By collaborating with Parasol Nutrition and GC Rieber/VivoMega, we’re demonstrating how practitioners can confidently deliver omega-3 solutions backed by biomarkers, solid science, and high-quality oils.”
More information about the Integrative Healthcare Symposium program can be found at: https://www.ihsymposium.com/conference-program/

Nestlé Health Science Launches Landmark Study to Uncover the Impact of Lifestyle on Gut Health

Nestlé Health Science, a global leader in the science of nutrition, announced today a longitudinal study designed to discover how lifestyle factors—specifically dietary fiber—shape the human microbiome and influence health.
The longitudinal collaboration study, FIBER-IMPACT, will enroll 60 healthy adults and their households for a 16-week observational period where participants will supplement their diets with chia seeds and provide stool and blood samples, while completing daily dietary and stress surveys and submitting meal photos. The research aims to evaluate how dietary fiber affects the gut's spore colony-forming units (SCFU), assess the effects of stress, identify host biomarkers, and explore the relationship between microbiome composition, metabolomic features, and overall health—all in the context of real-world lifestyles.
Bringing together leading experts from across the field, the study will be led by Principal Investigator Dr. Jason Goldsmith, Senior Director, Clinical Operations and Microbiome Sciences, Nestlé Health Science. The collaboration includes Dr. Thaddeus Stappenbeck, Chair of Inflammation and Immunity at Cleveland Clinic, focusing on the root causes of inflammatory and infectious diseases, Dr. Katrine Whiteson, Professor and co-Director of UCI Microbiome at UC Irvine, specializing in human-associated microbial and viral communities and the impact of dietary fiber, and Dr. Sonia Grego of Coprata, whose technology supports the study's innovative sample collection.
"This research will help unlock how daily habits and nutrition shape the microbiome, paving the way for future breakthroughs," said Dr. Goldsmith. Dr. Stappenbeck added: "By translating our discoveries on gut bacteria and immune health into this real-world study, we aim to advance new strategies for disease prevention." Dr. Whiteson remarked, "Our work shows fiber's powerful role in the microbiome. People want to take control of their health and this collaboration lets us see the impact of a very doable intervention in everyday life."
The study will leverage Coprata's innovative stool sampling tools and digital tracking, making participation less burdensome than traditional methods. All sample collection and data gathering are conducted under Institutional Review Board (IRB) oversight to ensure participant safety and privacy, as is standard for clinical research of this kind. Dr. Grego stated, "Coprata's technology lets participants collect samples conveniently and hygienically making research participation easier and more comfortable."
All participants will be appropriately compensated for their time and contributions. For more information about the study and to explore enrollment opportunities, visit ClinicalTrials.gov.
Nestlé Health Science invites additional partners to join in advancing microbiome science. Academic researchers interested in partnership opportunities can submit proposals through the Nestlé Health Science Medical Affairs website.

About the Collaborators
Nestlé Health Science
Nestlé Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestlé. We are committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Our extensive research network provides the foundation for products that empower healthier lives through nutrition. Headquartered in Switzerland, we have more than 12,000 employees around the world, with products available in more than 140 countries. For more information, please visit https://www.nestlehealthscience.us.

Department of Inflammation and Immunity, Cleveland Clinic
The Department of Inflammation and Immunity at Cleveland Clinic, focuses on the root causes of inflammatory and infectious diseases, with the goal of developing new therapies for conditions like inflammatory bowel disease and gut immunodeficiency. Learn more at https://www.lerner.ccf.org/inflammation-immunity/stappenbeck/.
Whiteson Lab, University of California, Irvine
The Whiteson Lab at UC Irvine studies human-associated microbial and viral communities, using metagenomics, metabolomics, and microbiology to understand how microbes and viruses affect human health, with a special focus on the impact of dietary fiber. Whiteson has led longitudinal dietary fiber interventions in her undergraduate classes, breast cancer survivors, and as part of UCI's Culinary Medicine program. Learn more at https://kwhiteson.bio.uci.edu/.
Coprata
Coprata is a health technology company advancing gut health monitoring with innovative solutions for research and personalized wellness. Its portfolio includes user-friendly stool collection tools, a rapid at-home gut health test, and a Smart Toilet for real-time health data collection. Learn more at https://www.coprata.com/for-research.
SOURCE Nestlé Health Science U.S.

NOW® Survey Uncovers The Wellness And Health Priorities Shaping Consumers' Supplement Use In 2026

Wellness is taking center stage in 2026, according to a new consumer survey commissioned by leading natural products manufacturer NOW® (Suzy.com, September 2025). The survey revealed that supplement use is at an all-time high, with 76% of participants now taking supplements daily and 44% reporting increased use in 2025 compared to 2024, reflecting a continued shift toward proactive holistic wellness practices for longevity. When asked about their health priorities for 2026, consumers cited general health (55%), immune health (47%), energy support (44%), stress and mood support (41%), and weight management (35%) as their top priorities for supplement support.
"At a time when consumers are focusing on their health and wellness now more than ever before and relying on supplements to support their wellness goals and fill in nutrition gaps, NOW can be that reliable and affordable brand they reach for," said DJ Blatner, NOW Wellness Expert and Registered Dietitian Nutritionist (RDN). "NOW is fully transparent when it comes to prioritizing their industry leading quality protocols, which is imperative when it comes to earning consumer trust. They perform more than 31,000 tests every month from raw ingredients to finished products to ensure what's on the label is in the bottle, and nothing else. I like to say they're a total wellness solution anyone can feel good about."
So, with so many options available, where should people start? To simplify, Blatner recommends a supplement starter kit to help consumers meet their general health needs, then broadening to support their additional wellness priorities. As always, it's important to consult a doctor and/or healthcare professional when starting or changing a supplement routine:
General Health*: Blatner considers five categories for her starter kit, all of which offer a variety of delivery formats and options to suit individual preferences, including a multivitamin, vitamin D (like this NEW Vitamin D3 + K2 Chewable for bone and cardiovascular support*), magnesium, omega-3 (80 percent of Americans aren't getting enough in their daily diet), and a probiotic (NOW is one of the only supplement companies to test for exact DNA strains via their RiboPrinter technology).
Additional Wellness Priorities and Supplements to Consider:

• Immune Health*: NOW® NAC, Quercetin & Zinc supports normal, balanced immune system function and promotes the formation of glutathione to act as a free radical neutralizer.*
• Energy Support*: NOW® Sports Sustained Energy delivers energy production and mental alertness by offering a sustained release of caffeine and other supportive nutrients, while NOW® Vitamin B-12 Shots are designed for on-the-go support with an energizing 10,000 mcg blast of Vitamin B-12.*
• Stress and Mood Support*: Clinically validated NOW® Calm & Focus with Zembrin® & GABA can help maintain emotional stability while enhancing certain cognitive functions, such as memory and mental flexibility.*
• Weight Management*: NOW® Prebiotic Fiber with Fibersol®-2 may support normal levels of the appetite-regulating hormone GLP-1 in healthy individuals, while NOW® Berberine Glucose Support is combined with MCT oil for optimal berberine absorption and supports glucose and lipid levels already within the normal range.*

As Blatner notes above, finding trusted supplements is so important, yet the survey also revealed nearly half (44%) of respondents worry about safety and quality, and more than one-third (35%) aren't sure which brands to trust.
"I may be a dietitian recommending supplements, but I'm also a consumer with so many choices in the supplement aisle and online, so there are six checks I do personally and also recommend my clients consider to help them be more educated and confident shoppers," Blatner added.
Check for Certifications: Look for GMP (Good Manufacturing Practices) and third-party certification logos like Informed Sport or USDA Organic on the label or website. NOW exceeds FDA-established GMP standards and invests in third-party seals and certifications.
Avoid Outlandish Claims or Proprietary Blends: Steer clear of supplements with exaggerated claims or proprietary blends. NOW supports its label claims with scientific data.
Review Product Testing Information: Choose brands that share detailed quality control and testing processes online. For example, NOW conducts over 31,000 tests monthly, from raw ingredients to finished products, in their third-party ISO-accredited labs, in addition to partnering with trusted third-party labs for independent verification. Learn more about their quality commitment here. Check the brand website and if they don't share any info on testing or quality, that should be an immediate red flag.
Look for Trademarked Ingredients: Brands that use some trademarked ingredients enhance credibility, safety, and efficacy, as they are supported by clinical research from the ingredient suppliers.
Buy from Reliable Sources: Purchase directly from the manufacturer's website or trusted retailers to ensure product authenticity and proper handling.
Check for Expert Support: Make sure the brand is backed by trusted experts with real credentials. If experts are mentioned, take a moment to look them up and confirm they're qualified in health and wellness.
For more information about NOW, from products to its world-class labs, visit: nowfoods.com. NOW products are available on their website, Amazon, or at fine health food stores and natural retailers nationwide.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About NOW®
Founded by Elwood Richard in 1968 on the belief that natural is better, NOW has grown from a small family operation into one of the most highly respected manufacturers in the natural products industry. Still a family-owned company today, NOW provides customers with a comprehensive approach to wellness by offering more than 1,500 dietary supplements, functional foods, sports nutrition, health and beauty products, and essential oils. NOW is committed to offering safe, affordable products of the highest quality and is a highly regarded advocate in the natural products industry. After nearly 60 years in the natural products industry, NOW remains committed to its original mission – to provide value in products and services that empower people to lead healthier lives.

New Study Links Higher Omega-3 Levels to Lower Risk of Depression & Anxiety

A new cross-sectional analysis published in The Journal of Nutrition provides compelling evidence that higher plasma levels of omega-3 fatty acids—particularly EPA-rich, non-DHA omega-3s—are associated with significantly lower rates of depression and anxiety. The study, led by researchers at the Fatty Acid Research Institute (FARI), evaluated 258,354 adults with plasma fatty acid measurements and 468,145 adults with detailed fish oil supplement use in the UK Biobank, representing the largest biomarker-based mental health analysis of its kind.
Critical depression and anxiety outcomes were drawn from physician-diagnosed ICD-10 codes, not self-report—making these findings more clinically relevant. Statistical models adjusted for age, sex, ethnicity, BMI, smoking, diet, alcohol use, exercise, socioeconomic status, and other covariates.
The findings show that individuals with the highest omega-3 status (i.e., Omega-3 Index) had 15–33% lower odds of a lifetime history of depression and 19–22% lower odds of a lifetime history of anxiety, compared with those with the lowest levels. The non-DHA omega-3 fraction—primarily EPA—showed some of the strongest associations with reduced risk.
The study also found that fish oil supplement users had 9–10% lower risk of a history of depression or anxiety, and 20% lower risk of recent anxiety, independent of fish intake.
Study Highlights

• Higher plasma omega-3 levels (total omega-3s, DHA, and non-DHA omega-3s) were consistently associated with lower odds of historical depression and anxiety.
• Non-DHA omega-3s (a proxy for EPA) had some of the strongest inverse associations, suggesting a particularly important role for EPA in mental health.
• Fish oil supplement users showed significantly lower risk for depression and anxiety, independent of oily fish consumption.
• Oily fish intake was also associated with reduced risk, but with weaker dose-response relationships compared to biomarkers—likely due to limitations of dietary self-reporting.

Lead author and President of the Fatty Acid Research Institute (FARI), Dr. Bill Harris, said “Our findings from more than a quarter-million adults show a clear and consistent link between higher omega-3 status and lower chance of having a history of both depression and anxiety. When you consider the biological roles of EPA and DHA in inflammation, neuronal function, and neurotransmitter signaling, these associations make a great deal of sense.”
“This study adds significant weight to the growing evidence that omega-3 fatty acids—especially EPA—may help protect mental health,” Dr. Harris added.
“The strength of this research lies in both its scale and its use of plasma omega-3 measurements,” said Nathan Tintle, PhD, Co-author, bio-statistician, and Executive Director of FARI. “The biomarker data give us a much clearer picture than self-reported diet alone, and the consistency across multiple omega-3 metrics strengthens confidence in the overall conclusions.”
Study Link:
Associations of Plasma Omega-3 Fatty Acid Levels and Reported Fish Oil Supplement Use with Depression and Anxiety: A Cross-Sectional Analysis from the United Kingdom Biobank
About OmegaQuant:
OmegaQuant is an independent, CLIA-certified lab that offers nutritional status testing to researchers, clinicians and the public. OmegaQuant performs analysis in Sioux Falls, SD, for commercial and academic research collaborators, and for consumers interested in monitoring their nutritional status in both blood and breast milk. Its goal is to offer the highest quality fatty acid analytical services to researchers and to provide simple tests of nutritional status to consumers, with the ultimate purpose of advancing the science and use of certain nutrients to improve health. Internationally, OmegaQuant works with the University of Stirling, based in the Scotland, to help process blood samples from Europe. Learn more @ www.omegaquant.com
About FARI:
FARI was established in 2020 as a non-profit foundation that brings together nutrition scientists and biostatistical experts with strong publication records and expertise in fatty acids to accelerate discovery of the relationship between fatty acids, especially omega-3s, and health. FARI is currently the only organization focused directly on discovering and publishing research evaluating the health effects of individual fatty acids. Learn more @ www.faresinst.org

Vitamin K2’s Proven Benefits are Growing, Yet Recognition has Room to Improve

The 5th Meeting of the Gnosis by Lesaffre Vitamin K2 Scientific Advisory Committee offers in-depth analyses of new studies and abstracts.
A cadre of researchers specializing in the biological activities of vitamin K2 menaquinone-7 (MK-7) gathered for the 5th semi-annual Gnosis by Lesaffre Vitamin K2 Scientific Advisory Committee meeting held in mid-November. During the meeting, they presented groundbreaking research, forthcoming study publications, and explored new marketing landscapes to further consumer education and motivate purchase.
The meeting, led by K2 pioneer Professor Leon Schurgers from Maastricht University, featured two main sessions: science and marketing.
Scientific Session
New study results support the benefits of MK-7 as MenaQ7® and highlight the importance of optimal extrahepatic vitamin K status, with several key findings that offer strong marketing potential. Fresh findings from new studies were presented by K2 experts Prof. Schurgers, Prof. Sola Bahous, Dr. Stefanos Roumeliotis, and Gnosis Industrial PhD Student Rudolf Bittner.
Data previously presented by Dr. Roumeliotis’ group at the 62nd ERA-EDTA congress showed that low vitamin K status is linked to inflammation, oxidative stress, and impaired cardiovascular function. [1] Oxidative stress emerged early in chronic kidney disease (CKD) and worsened as kidney function declined, closely paralleling increases in inactive Matrix Gla Protein (dp-ucMGP) and suggesting a link with vitamin K deficiency. [2] Cognitive impairment also appeared early and progressed with CKD severity, independently associating with higher dp-ucMGP, underscoring the connection between vitamin K deficiency and poorer clinical outcomes.[3] Together, these findings suggest that improving vitamin K status may be an important benefit to protect kidney health and reduce cardiovascular and cognitive complications in CKD.
Additionally, data collected from MenaQ7® interventional studies have shown benefits in arterial calcification and body composition, with full publications expected in 2026 (so stay tuned and follow us). Together, these findings suggest that improving vitamin K status—particularly by increasing vitamin K2 intake—may be a crucial strategy for enhancing kidney and overall health.
Dr. Katarzyna Maresz, scientific consultant for Gnosis and executive coordinator of the company’s Vitamin K2 Scientific Advisory Committee, commented, “This semi-annual event dedicated to advancing knowledge of K2 to drive product innovation is highly anticipated by leading clinical and scientific experts in the field. Experts presented ongoing observational and MenaQ7 clinical studies that will strengthen the message around extrahepatic vitamin K and general well-being, with emphasis on cardiovascular, kidney, and novel cognitive health.”
Marketing Session
The demand for products containing vitamin K2 (MK-7) is soaring worldwide, but with differing priorities. Beyond traditional supplement formats, UK brands have a new focus on innovative product concepts such as salad dressings, shots, and ‘health biscuits,’ as examples. The Philippines is focused on increasing awareness and knowledge of K2’s benefits for cardiovascular and kidney health, whereas in Vietnam, the emphasis is on bone health and growth, particularly in children.
“Overall, the global K2 market is experiencing strong growth, driven by increasing awareness of its benefits for bone and cardiovascular health, with further expansion expected in the coming years,” added Xavier Berger, Gnosis Global Category Manager.
Conclusion
“The data collected and presented by the experts, as well as the planned future research, have high marketing and robust formulation value for vitamin K2 as MenaQ7,” Dr. Maresz stated. “We also identi?ed important gaps, such as the lack of clear recommendations and the still limited recognition of this important nutrient. Despite numerous clinical studies and meta-analyses demonstrating clear benefits of vitamin K2 —for example, in bone health, this shows there is still a lot of work to do, but the outlook for future use of K2 remains very promising."
References:
1 Neofytouet et al. The association of dephosphorylated, uncarboxylated Matrix Gla Protein with vascular calcification and oxidative stress in chronic kidney disease patients. Nephrol Dial Transplant. 2025 Oct;40(Suppl 3).
2 Tsinari A, Neofytou I, Varouktsi G, et al. The association of malondialdehyde, catalase and superoxide dismutase with kidney function and vitamin K status in chronic kidney disease. Nephrol Dial Transplant. 2025;40(Suppl 3).
3 Varouktsi et al. The association of cognitive dysfunction with markers of oxidative stress and vitamin K deficiency in chronic kidney disease patients. Nephrol Dial Transplant. 2025;40(Suppl 3).
About Gnosis by Lesaffre
By using the power of microorganisms and biotransformation processes, Gnosis by Lesaffre cultivates unique active ingredients through fermentation, as well as probiotics and nutritional, functional yeasts that benefit human health, longevity, and well-being. Our high-quality solutions are meticulously studied, replicable, and reliable as we scale our collaboration with nutraceutical and pharmaceutical brands to develop revolutionary products that help customers thrive. 
Gnosis by Lesaffre – Think like Nature to raise the standard of human health. http://www.GnosisByLesaffre.com
About Lesaffre
A key global player in fermentation for more than a century, Lesaffre, with a 3 billion euro turnover, and established on all continents, counts 11,000 employees and more than 90 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms.
To nourish 9 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe that fermentation is one of the most promising answers to this challenge.
Lesaffre – Working together to better nourish and protect the planet. http://www.Lesaffre.com